Sygnature Discovery appoints Dr Andy Black as Non-executive Chairman

Sygnature Discovery has appointed Dr Andy Black as non-executive Chairman. Andy will work closely with the Board and senior team to further develop our future growth strategy.

Andy Black.PNG

In October 2017, Phoenix Equity Partners invested into Sygnature to accelerate its growth. Andy will work closely with the team at Phoenix and Sygnature to lead its ambitious plans to become the front-runner in the global drug discovery services market.

Andy brings over 20 years of experience in life sciences to Sygnature Discovery, including 13 years at CEO and Board level. He has a proven track record in entrepreneurship, devising, and leading strategic change, and possesses functional expertise in numerous areas, including pharmaceutical research, clinical development, drug regulation, pharmacovigilance and quality, and compliance.

Andy joins Sygnature from Kinapse, where he was a Co-founder and the CEO. Kinapse is an international business providing R&D advisory and implementation services to the life sciences industries. Kinapse is now a team of approximately 700 staff and works with the top 10 global pharmaceutical companies and the European Medicines Agency. The company received six Fast Track Awards as one of the most successful private companies in the UK and was also recognised as one of 10 International Growth Heroes by London & Partners in 2016.

Andy is also Head of Strategic Industry Partnerships at King’s College London where he is responsible for developing large-scale translational research partnerships between leading life sciences companies and King’s Health Partners.

Prior to Kinapse, Andy trained as a surgeon in the National Health Service after gaining his medical degree (with distinction in surgery) from Guy’s Hospital, London, and he is a Fellow of the Royal College of Surgeons of England

Commenting on his appointment, Andy said:

“I am delighted and privileged to be taking on the role of Chairman at Sygnature Discovery. I look forward to working with the Board and senior leadership team in Nottingham as well as with our partners at Phoenix.

“I hope that I can use my diverse experience in life sciences to lead Sygnature to further growth and develop our high value services in global drug discovery, keeping in mind the firm’s ultimate objective of becoming an undisputed leader in this cutting-edge sector.

“Sygnature is a truly innovative company with a positive and dynamic working culture which is helping to facilitate the exciting progress it is making within drug discovery.”

Founder and Chief Executive of Sygnature Discovery, Dr Simon Hirst commented:

“Andy is a highly experienced strategist with an entrepreneurial outlook who brings a great level of expertise, as a thought leader in a wide variety of life science domains.

“We are delighted to welcome him to the Board and believe that his strategic vision will be invaluable as we work to further develop our partnership with Phoenix to drive Sygnature’s development and provide an enhanced service for our customers.”